Regulatory class action lawsuit

Soleno Therapeutics Faces Class Action Lawsuit

Analysis based on 13 articles · First reported Mar 07, 2026 · Last updated Mar 11, 2026

Sentiment

-40

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The class action lawsuit against Soleno Therapeutics, coupled with negative reports and patient safety concerns, has led to significant declines in Soleno Therapeutics' stock price. This event highlights the risks associated with biopharmaceutical companies and their clinical trial disclosures, potentially increasing scrutiny on similar firms.

Biotechnology Legal Services

Event Summary

Robbins Geller Rudman & Dowd LLP LLP has announced a class action lawsuit against Soleno Therapeutics, Inc. on behalf of purchasers of its common stock between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno Therapeutics and its executives violated the Securities Exchange Act of 1934 by failing to disclose significant safety concerns related to its drug, DCCR, for treating Prader–Willi syndrome. Specifically, the lawsuit claims Soleno Therapeutics downplayed evidence of excess fluid retention in clinical trial participants and that the drug posed greater safety risks than disclosed. Negative news, including a critical report from Scorpion Capital LLC and the disclosure of a patient death after taking DCCR, led to substantial drops in Soleno Therapeutics' stock price. The lawsuit also cites a 'disruption' in DCCR's launch trajectory and concerns within the PWS community.

Key Actions

100 Robbins Geller Rudman & Dowd LLP filed class action lawsuit Soleno Therapeutics

90 Soleno Therapeutics stock price declined

90 Soleno Therapeutics disclosed patient death

80 Scorpion Capital published critical report Soleno Therapeutics

Entities Involved

stock

Soleno Therapeutics

Soleno Therapeutics is facing a class action lawsuit for allegedly misrepresenting safety concerns related to its drug DCCR, leading to significant stock price declines and reputational damage. The lawsuit claims the company downplayed risks of excess fluid retention and a patient death after taking DCCR.

Importance 100 Sentiment -70

priv

Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP LLP is representing the purchasers of Soleno Therapeutics common stock in a class action lawsuit, seeking to appoint a lead plaintiff. The firm specializes in securities fraud and shareholder rights litigation.

Importance 80 Sentiment 60

priv

Scorpion Capital

Scorpion Capital LLC published a critical report on Soleno Therapeutics' DCCR and its Phase 3 clinical trial program, alleging the drug was worthless and toxic. This report contributed to a nearly 12% decline in Soleno Therapeutics' stock price.

Importance 70 Sentiment 50

govactor

United States===United States Securities and Exchange Commission

Soleno Therapeutics filed a current event report on Form 8-K with the United States===United States Securities and Exchange Commission, disclosing a patient death after taking DCCR. This filing is a regulatory requirement for publicly traded companies.

Importance 30 Sentiment 0

exch

Nasdaq

Soleno Therapeutics' common stock is traded on Nasdaq, and its price declined significantly following negative news related to the DCCR drug and the class action lawsuit.

Importance 10 Sentiment 0

Relationships

Soleno Therapeutics related ↔ United States===United States Securities and Exchange Commission

Soleno Therapeutics related ↔ Robbins Geller Rudman & Dowd LLP

Soleno Therapeutics related ↔ Scorpion Capital

Robbins Geller Rudman & Dowd LLP related ↔ Scorpion Capital

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard